BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting
August 7, 2024
News Release
BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting
COPENHAGEN, DENMARK and BOSTON, MA, USA, August 7, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today that, in connection with the release of its Interim Report for the second quarter ending June 30, 2024, the Company’s management team will host an online investor presentation on August 15, 2024, at 10:30 CEST via HC Andersen Capital. Investors interested in attending the webcast may register here: https://www.inderes.dk/videos/bioporto-opdatering-pa-q2-2024.
Additionally, the Company’s management team will host a physical investor meeting on August 15, 2024, at 15:00 CEST at the Company’s address at Tuborg Havnevej 15, ground floor, 2900 Hellerup, Denmark. Investors interested in attending the physical investor meeting can register by writing to [email protected].
To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/.
Investor Relations
Tim Eriksen, Zenith Advisory, +45 4529 0000, [email protected]
Ashley Robinson, LifeSci Advisors, +1 617 430 7577, [email protected]
About Acute Kidney Injury
Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/.
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels which rise in relation to kidney injury, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit http://www.bioporto.com.
